Baseline characteristics (n = 500) | |||
---|---|---|---|
Demographics | Medication previous to TEE | ||
Age (years) | 69 ± 10 | Oral Anticoagulation | 40.6% (203) |
Age ≥ 75 years | 31% (155) | Antiplatelet agents | 46.4% (232) |
Age 65–74 years | 39.8% (199) | 1-3 doses of enoxaparine | 33.8% (169) |
Body Mass Index (Kg/m2) | 26.6 ± 8.8 | Echocardiographic characterization | |
Female gender | 34.2% (171) | LA AP diameter (cm) | 4.7 ± 0.7 |
Clinical data | LA area (cm2) | 27.6 ± 7.1 | |
Hypertension | 81.8% (409) | LA ellipsoid volume (cm3) | 74.1 ± 29.0 |
Diabetes | 23.6% (118) | LA 1P area-length volume (cm3) | 113.8 ± 47.7 |
Previous Stroke/TIA | 14.8% (74) | LA 2P area-length volume (cm3) | 104.1 ± 38.1 |
Congestive heart failure | 54.8% (274) | LV ejection fraction ≥55% | 73.6% (368) |
Vascular diseasea | 52% (260) | LAA thrombus | 11.1% (55) |
CHADS2 | 1.9 ± 1.2 | LAA low flow velocities | 13.2% (66) |
CHA2DS2-VASc | 3.2 ± 1.7 | Dense SEC | 24% (120) |
Pacemaker or ICD | 19.6% (98) | LA ABN | 29.6% (148) |
Estimated current AF episode duration | Laboratorial evaluation | ||
≤ 48 hours | 7% (35) | Haemoglobin (g/dL) | 13.2 ± 1.8 |
< 1 week | 19.6% (98) | Platelets (103/μL) | 219.7 ± 85.5 |
< 1 month | 36% (180) | INR | 1.5 ± 0.8 |
> 6 months | 35.8% (179) | INR ≥ 2.0 | 20.8% (104) |
> 1 year | 26.8% (134) | GFR (mL/min/1.73 m2) | 62.4 ± 33.0 |